Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones01-22 05:38

DJ Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. $(VRTX)$ advanced 1.40% to $427.89 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.88% to 6,049.24 and the Dow Jones Industrial Average rising 1.24% to 44,025.81.

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Inc. closed 17.69% below its 52-week high of $519.88, which the company achieved on November 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as AbbVie Inc. $(ABBV)$ rose 0.61% to $172.61, Krystal Biotech Inc. (KRYS) rose 2.13% to $151.55, and Arcturus Therapeutics Holdings Inc. $(ARCT)$ fell 2.26% to $16.41.

Trading volume (1.5 M) remained 92,658 below its 50-day average volume of 1.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled January 21, 2025.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

January 21, 2025 16:38 ET (21:38 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment